BIOCYTOGEN
21.6.2024 12:51:24 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TensorX Reaches $5 Million and Appoints Tim Grant as CEO as Demand for Sovereign AI Accelerates8.10.2026 10:19:00 CEST | Press release
Tim Grant, Executive Chairman since May, is appointed Chief Executive Officer as the Dublin company serves more than 5,000 paying customers and expands its infrastructure across EuropeThe appointment comes as AI usage on TensorX’s shared inference platform has grown 171-fold in seven months as monthly token volume reaches 1.1 trillion TensorX, the Irish sovereign AI inference company, has reached $5 million in revenue as demand for private AI infrastructure continues to grow across Europe and beyond. Tim Grant, who joined the company as Executive Chairman in May, has been appointed Chief Executive Officer to lead as its growth accelerates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008373051/en/ Tim Grant, Executive Chairman since May, is appointed Chief Executive Officer as the Dublin company serves more than 5,000 paying customers and expands its infrastructure across Europe. TensorX is a neocloud that delivers infe
Aresbank Strengthens Trade Finance and Correspondent Banking Compliance with SymphonyAI8.10.2026 09:55:00 CEST | Press release
Specialist corporate bank connecting Europe, Middle East and North Africa, adopts a platform built to scale as regulations and trade volumes evolve As a specialized corporate and trade finance bank in the MENA region, Aresbank manages risk and moves money across some of the most sensitive trade corridors between Europe, the Middle East and North Africa. Operating in a highly regulated environment, Aresbank turned to SymphonyAI, a global leader in Vertical AI whose financial crime compliance platform already spans retail, commercial and correspondent banking, to strengthen its transaction monitoring framework across trade finance and correspondent banking. Headquartered in Madrid, the bank's business centers on trade instruments, including correspondent banking, documentary credits, international guarantees and multi-currency credit lines that connect European and MENA markets. Correspondent banking carries a distinct risk profile, and trade finance flows in the region remain a focus fo
Fortune Media and Great Place To Work Name Experian As One Of The ‘100 Best Companies to Work For Europe’ in 2026 for Second Year8.10.2026 09:00:00 CEST | Press release
Great Place To Work® and Fortune Europe have recognised Experian as one of the Fortune 100 Best Companies to Work For™ Europe for the second-year running. The 100 Best Companies to Work For Europe list is a comprehensive recognition for business excellence and employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Great Place To Work evaluates confidential feedback from employees, validating against HR data from participating companies. Only companies with consistently high survey responses from employees — regardless of their role, department, or status in the company — are honored with placement on the list. Eligible companies have 500 or more employees and were represented on at least one national Best Workplaces™ List in Europe. Jacky Simmonds, Chief People Officer, Experian, said: “We are thrilled to being named one of the Fortune 100 Best Companies to Work For™ in Europe for the second year in a row. It’s an incredibly proud moment for us at Experian
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 08:32:00 CEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 07:30:00 CEST | Press release
Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom